文献速递脑血管病

新型径向可调取栓支架TIGER试验主要结果

New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial.
PubMed 文献 · Stroke · 2021-03-19

TIGER试验为单臂、前瞻性、多中心研究,纳入160例大血管闭塞急性缺血性卒中患者,比较Tigertriever取栓支架与基于6项关键研究设定的疗效和安全性目标值。主要疗效终点成功率84.6%,优于63.4%目标值(非劣效P<0.0001;优效P<0.01);主要安全终点发生率18.1%,非劣效于30.4%目标值(P=0.004)。

要点

  • Tigertriever取栓支架3次内成功再灌注率达84.6%,优于预设目标值。
  • 90天死亡与症状性颅内出血复合终点率18.1%,非劣效于目标值。
  • 首过成功再灌注率57.8%,90天良好临床结局率58%。

核心结论

  • Tigertriever在适合机械取栓的大血管闭塞性卒中患者中高效且安全。

研究设计与样本

  • 单臂、前瞻性、多中心试验,纳入160例大血管闭塞急性缺血性卒中患者,比较Tigertriever与源自6项近期关键研究的疗效和安全性目标值。

主要发现

  • 主要疗效终点(3次内改良脑缺血溶栓评分2b-3)在主要研究阶段组达84.6%,对比63.4%目标值和73.4%历史率(非劣效P<0.0001;优效P<0.01)。
  • 首过成功再灌注率为57.8%。
  • 所有干预后成功再灌注(改良脑缺血溶栓评分≥2b)达95.7%,优秀再灌注(2c-3)达71.8%。
  • 主要安全复合终点(90天全因死亡和症状性颅内出血)率为18.1%,对比30.4%目标值和20.4%历史率(非劣效P=0.004;优效P=0.57)。
  • 90天良好临床结局(改良Rankin量表评分0-2)达58%。

关键数值与推荐

  • 入组标准:急性缺血性卒中,美国国立卫生研究院卒中量表评分≥8,大血管闭塞,发病8小时内。
  • 主要疗效终点为核心实验室判定的改良脑缺血溶栓评分2b-3且使用Tigertriever不超过3次。
  • 主要安全终点为90天全因死亡和症状性颅内出血的复合终点。

临床怎么用

  • Tigertriever可作为大血管闭塞急性缺血性卒中机械取栓的可选支架取栓装置。

局限性

  • 单臂设计,未与Trevo和Solitaire进行随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The Tigertriever is a novel, radially adjustable, fully visible, stentriever that permits the operator to align radial expansion with target vessel diameters. This multicenter trial compared the Tigertriever’s effectiveness and safety compared with established stent retrievers. METHODS: Single arm, prospective, multicenter trial comparing the Tigertriever to efficacy and safety performance goals derived from outcomes in 6 recent pivotal studies evaluating the Solitaire and Trevo stent-retriever devices with a lead-in and a main-study phase. Patients were enrolled if they had acute ischemic stroke with National Institutes of Health Stroke Scale score ≥8 due to large vessel occlusion within 8 hours of onset. The primary efficacy end point was successful reperfusion, defined as core laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia score 2b-3 within 3 passes of the Tigertriever. The primary safety end point was a composite of 90-day all-cause mortality and symptomatic intracranial hemorrhage. Secondary efficacy end points included 3-month good clinical outcome (modified Rankin Scale score 0–2) and first-pass successful reperfusion. RESULTS: Between May 2018 and March 2020, 160 patients (43 lead-in, 117 main phase) at 17 centers were enrolled and treated with the Tigertriever. The primary efficacy end point was achieved in 84.6% in the main-study phase group compared with the 63.4% performance goal and the 73.4% historical rate (noninferiority P<0.0001; superiority P<0.01). The first pass successful reperfusion rate was 57.8%. After all interventions, successful reperfusion (modified Thrombolysis in Cerebral Ischemia score ≥2b) was achieved in 95.7% and excellent reperfusion (modified Thrombolysis in Cerebral Ischemia score 2c-3) in 71.8%. The primary safety composite end point rate of mortality and symptomatic intracranial hemorrhage was 18.1% compared with the 30.4% performance goal and the 20.4% historical rate (noninferiority P=0.004; superiority P=0.57). Good clinical outcome was achieved in 58% at 90 days. CONCLUSIONS: The Tigertriever device was shown to be highly effective and safe compared with Trevo and Solitaire devices to remove thrombus in patients with large-vessel occlusive stroke eligible for mechanical thrombectomy.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Gupta R, Saver JL, Levy E, et al. New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial. Stroke. 2021. PMID: 33739136. doi:10.1161/STROKEAHA.121.034436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。